PPT-Access to medicines in Europe

Médecins du monde Doctors of the World International Network François Berdougo Harm Reduction Working Group an independent international movement working across the world 78 countries both at home 169 . Global context of drug regulation. Dr Lembit Rägo. Coordinator. Quality Assurance and Safety: Medicines. Essential Medicines and Health Products. World Health Organization. E-mail: . ragol@who.int. Médecins du monde – Doctors of the World International Network. François Berdougo – Harm Reduction Working Group.  . an . independent international movement working across. . the world (78 countries), both at home (169 . for asthma. WHO . Technical. Briefing . Seminar. on Essential . Medicines. & Health . Products. , Nov. 2013. Christophe Perrin, . Pharmacist. , MPH – IUATLD (The Union). Asthma. . - Global . Concept/Process and Update on EML 2015. WHO Technical Briefing Seminar. Nicola Magrini – WHO, EMP. November 4, 2014 – WHO Geneva. Essential Medicines. Guiding principle:. . A limited range of carefully selected essential medicines leads to better health care, better medicines management, and lower costs. for asthma. WHO . Technical. Briefing . Seminar. on Essential . Medicines. & Health . Products. , Nov. 2013. Christophe Perrin, . Pharmacist. , MPH – IUATLD (The Union). Asthma. . - Global . Stops AIDS National Gathering . 1st November 2014. Aliénor Devali. ère. Health. Action International (HAI) Europe. This document arises from HAI Europe’s Operating Grant 2014, which has received funding from the . Gilles . Forte. Coordinator, Policy, Access and Use Team. Essential . Medicines . and . Health Products. . WHO . mandate . within the . International . Drug Control Conventions. 1961 . Single Convention on Narcotic Drugs (Article 3). PARTNERSHIP. Medicines for Europe Vision 2020 . Our 5 pillars. 2. PATIENTS. Medicines For Europe . VISION. QUALITY. VALUE. SUSTAINABILITY. Pressure on EU budgets . Reduction. of . healthcare. . spending. WHO EMP and NVI Departments. Access to NCD essential medicines . on the global agenda. Access to chronic disease medicines is required for the fulfilment of MDG8. Governments, in collaboration with the private sector, should give greater priority to treating chronic diseases and improving the accessibility of medicines to treat them (MDG Report 2009). sustainably and equitably financed. Summary Discussion…1. What information needed to estimate cost program of medicines benefits. MBM . Ned to estimate the total economic cost of setting up a MBM program. for asthma. WHO . Technical. Briefing . Seminar. on Essential . Medicines. & Health . Products. , Nov. 2013. Christophe Perrin, . Pharmacist. , MPH – IUATLD (The Union). Asthma. . - Global . IPC Meeting . 4 to 6 . June. 2014. Essential Medicines and Health Products Department (EMP) . . . October. 2013. . Office of the . Once . the protection of the product . expires for . example, patents or regulatory protection such as data . exclusivity, . the company no longer has exclusive rights to sell the medicine. . Other . Dr. Richard Torbett. Chief Economist, EFPIA. China/ EU Pharmaceutical Industry Forum. Shanghai, . 16 May 2015. Policy debate on health in recent years has been dominated by cost containment. Health & Growth.